Dennis Ding
Stock Analyst at Jefferies
(1.20)
# 3,736
Out of 5,045 analysts
15
Total ratings
40%
Success rate
-2.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $19.58 | +2.15% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $41.12 | -36.77% | 2 | Sep 3, 2025 | |
| INDV Indivior | Assumes: Buy | $20 | $29.13 | -31.34% | 1 | Jul 22, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $43.28 | +27.08% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.45 | +451.72% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $30.12 | +16.20% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $8.91 | +102.13% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.84 | +44.78% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $5.65 | +6.19% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $5.52 | +352.90% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $72.26 | -69.55% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $38.72 | -38.02% | 1 | Dec 19, 2022 |
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $19.58
Upside: +2.15%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $41.12
Upside: -36.77%
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $29.13
Upside: -31.34%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $43.28
Upside: +27.08%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.45
Upside: +451.72%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $30.12
Upside: +16.20%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $8.91
Upside: +102.13%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.84
Upside: +44.78%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $5.65
Upside: +6.19%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $5.52
Upside: +352.90%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $72.26
Upside: -69.55%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $38.72
Upside: -38.02%